
Shideh Khangholi¹, Mehdi Mahdavi²,³, Mohammad Hossein Yazdi²,³,₄*, Ahmad Reza Shahverdi⁵

1. Department of Microbiology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
2. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
3. Immunotherapy Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
4. Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
5. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

* Corresponding Author:
Mehdi Mahdavi, PhD.
Address: Recombinant Vaccine Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Tel: +98 (912) 6850269
E-mail: mahdavivac@gmail.com

Mohammad Hossein Yazdi, PhD.
Address: Recombinant Vaccine Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Tel: +98 (21) 66482706
E-mail: mh-yazdi@sina.tums.ac.ir

ABSTRACT

Background: Brain tumors can be serious and life-threatening when they are treated effectively. Many therapeutic approaches, such as chemotherapy, radiotherapy, and surgery have been used to treat brain tumors. In this regard, selenium supplements have been reported effective.

Methods: Selenium Nanoparticles (SeNPs) were produced in two forms of synthetic and biogenic to evaluate their cytotoxicity on brain glioblastoma cell lines. A-172 cell line was cultured in Dulbecco's Modified Eagle Medium (DMEM) medium. The cytotoxicity of the synthetic and biogenic SeNP was assessed by MTT assay.

Results: There was a significant difference between the group treated with biogenic and synthetic SeNP compared with non-treated cells after 24, 48, and 72 h. Both biogenic and synthetic SeNP increased Bax gene and decreased Bcl-2 gene expression.

Conclusion: It seems that biogenic SeNP was more lethal than its synthetic form. Therefore, it should be considered that the method of NP construction may be an important parameter for its bioactivity.

1. Introduction

Brain tumor is an abnormal mass of tissue in the brain, which is possibly benign or malignant [1]. Treatment of brain tumors is associated with some side effects. Therefore, alternative approaches should be considered. Selenium is used as a supplement and has been suggested for cancer prevention [2]. Cancer prevention afforded by selenium is through DNA protection from anti-oxidant substances and regulating cell cycle progression. Also, selenium supplementation can enhance cytotoxic-
ity activity of CD8+ T cells against tumor cells [3]. In this regard, it has demonstrated that T cell receptor and IL-2 production is enhanced by selenium in medium culture. Furthermore, it could increase glutathione peroxidase and thoredoxin reductase 1 activity as antioxidants to suppress inflammatory circumstances [4]. It has been shown that the nanostructure of the chemical agents is more bioactive than their oxidative forms. In this regard, selenium nanostructure has found with lower toxicity and higher bioactivity in vitro and in vivo. In this respect, nanotechnology can be used to generate nanomaterials that are more bioactive [5]. SeNPs can be synthesized by biogenic and synthetic methods. Biogenic NPs could be produced through the utilization of microorganisms, especially bacteria that can convert selenite ion to SeNPs [6]. Synthetic SeNP can be produced in the presence of reducing agents, such as ascorbic acid and lactose. In this condition, selenium dioxide will be reduced and synthetic SeNPs appear in the presence of a reducing agent [7].

This study aimed at investigating the cytotoxicity effect of the biogenic and synthetic SeNPs on the A-172 cell line and its cell death mechanism.

2. Materials and Methods

A-172 cell line

A-172 cell line (human brain glioblastoma) was prepared from the National Cell Bank of Pasteur Institute of Iran (Tehran, Iran). The frozen cell sample was defrosted and the cells transferred into the complete Dulbecco's Modified Eagle Medium (DMEM) medium cell culture in an incubator with 5% CO2 at 37°C.

Fabrication of the biogenic SeNP

Biogenic SeNP was produced according to our laboratory framework as reported previously [8]. Briefly, Lactobacillus brevis was cultivated in MRS broth (Merck, Germany) at 37°C and after overnight incubation, selenium dioxide at a final concentration of 200 mg/L was added and the culture continued for 72 h. The bacteria suspension was collected by centrifugation at 4000×g for 15 min, and the pellet washed three times with PBS buffer. The obtained pellet was disrupted by adding liquid nitrogen and SeNPs were harvested with N-octyl alcohol-water extraction method. Isolated SeNPs were physically characterized for particle size and zeta potential (data are not shown).

Synthetic SeNP preparation

Synthetic SeNP was produced as reported previously [9]. In brief, selenium dioxide solution (5.2 mM) was prepared and then an aqueous ascorbic acid solution (5.2 mM) was slowly added to the selenium solution with continuous stirring at 300 rpm. Later, the mixture was centrifuged and the pellet washed three times with double-distilled water. The synthetic SeNPs were characterized physically for particle size and zeta potential (data are not shown).

Toxicity of the biogenic and synthetic SeNPs on A-172 cell line

Human brain glioblastoma, A-172 cell suspension in complete DMEM medium (Gibco, Germany), was adjusted to 2×105 cells/ml. Initially, 100 µl of the suspensions containing 2×104 cells were put in a 96-well plate (Greiner, Germany) and the biogenic and synthetic SeNPs at the concentrations of 0, 25, 50, 100, 200, 300 and 400 µg/ml were added to the cells at a final volume of 200 µl and the plates incubated at 37°C with 5% CO2. The experiments were performed in triplicate and after 24, 48 and 72 h. Cell toxicity was measured by the MTT assay. Briefly, after incubation, 20 µl of the MTT solution (5 mg/ml in PBS) was added to the wells in dark and the incubation continued for 4 h. The supernatant was then removed carefully and 100 µl of DMSO was added to each well to dissolve formazan crystals. The absorbance was measured at 540 nm by a microplate spectrophotometer (AWAINESS technology, USA).

BCL2 and Bax genes expression

As mentioned, the cells were treated with biogenic and synthetic SeNPs at IC50 concentration of 100 µg/ml and after 48 and 72 h, cellular RNA was extracted and then cDNA was synthesized using cDNA synthesis Kit (Yekta-Tajhiz, Iran) according to the manufacturer’s instruction. Then, β-actin, BCL2 and Bax genes expression was evaluated on cDNA samples by a real-time polymerase chain reaction. Beta-actin was utilized as a housekeeping gene to evaluate expression level of BCL2 and Bax genes in the treated glioblastoma cell lines.

Statistical analysis

The obtained data were analyzed using Graph pad prism V6.01 software. Mann-Whitney U test was applied to compare the significant differences at the significance level of 0.05. Values are presented as Mean±SD.
3. Results

Cytotoxicity of the biogenic SeNP on human brain glioblastoma cell line

Based on the results, treatment with the concentrations of 100, 300, and 400 µg/ml caused significant differences compared with the untreated cells (P<0.05) (Figure 1A). After 48 h of biogenic SeNP exposure, cytotoxicity was observed at a concentration of 400 µg/ml compared with untreated cells (P=0.0828) (Figure 1B). Also, after 72 h of biogenic SeNP exposure, cytotoxicity was found at the concentrations of 25, 100, 200, 300 and 400 µg/ml than untreated cells (P<0.0178) (Figure 1C).

Cytotoxicity of the synthetic SeNPs on Human brain glioblastoma cell line

The cells exposed to synthetic SeNPs at 400 µg/ml for 24h showed a significant difference with untreated cells (P=0.0021) (Figure 1D). There was a significant difference in A-172 cell lines treated with synthetic SeNPs at the concentrations of 100, 200, 300, and 400 µg/ml compared with untreated cells after 48 h (P<0.0057) (Figure 1E). Also, 72 h of treatment with synthetic

Figure 1. A-172 nervous cell lines

Treated with biogenic SeNP after 24 h (A), 48 h (B), and 72 h (C).
Treated with synthetic SeNP after 24 h (D), 48 h (E), and 72 h (F).
MTT assay was used to measure cytotoxicity.
SeNPs caused a significant difference at the concentrations of 100, 200, 300, and 400 µg/ml then untreated cells (P<0.0310) (Figure 1F).

**Results of the BCL2 and Bax Genes expression**

Results showed a 2.25- and 2.95-fold increase in Bax gene expression after 48 and 72 h of treatment with biogenic SeNP, respectively. Also, after 48 and 72 h of treatment with synthetic SeNP, a 1.95- and 2.15-fold increase was observed in Bax gene expression in comparison with the control gene expression.

The results indicated 0.651- and 0.505-fold increase in BCL2 gene expression in comparison with the control gene expression after 48 and 72 h of treatment with biogenic SeNP, respectively. Moreover, BCL2 gene expression showed 0.695- and 0.55-fold decrease after 48 and 72 h of treatment with synthetic SeNP, respectively (Figure 2).

**4. Discussion**

SeNP has proved with lower toxicity and higher bioactivity than oxide selenium [10]. Our results showed the toxicity of biogenic SeNP on A-172 cell lines after 24, 48 and 72 h of treatment. Shamsi et al. study showed the suppression of breast cancer after the treatment of 4T1 cell lines with biogenic SeNP [9]. Faghfuri et al. reported that biogenic SeNP a dose of 200 µg caused the most effective responses against tumor cells [8]. A Lactobacillus plantarum strain enriched with biogenic SeNP showed higher IL-12, TNF-α and IFN-γ levels and promoted natural killer cells activity in mice model of breast cancer [11]. These findings confirm the anti-tumor effect of biogenic SeNP.

Synthetic SeNP showed cell toxicity effect on tumor cells after 24, 48, and 72 h. The anti-tumor effect of synthetic SeNP has been reported, which is consistent with our results. These findings showed that both derived SeNPs had cell toxicity effect on the human brain glioblastoma cell line. Biogenic and synthetic SeNP increased both Bax and BCL2 genes expression levels after 48, and 72 h. Bax gen, as a pro-apoptotic gene, can eliminate tumor cells by inducing apoptosis pathway and BCL2 inhibits the apoptosis process in tumor cells, which promotes invasion and metastasis in tumor cells [12, 13]. Therefore, a reduction in BCL2 gene expression in glioblastoma cells and an increase in Bax gene expression indicate the cytotoxicity effect of biogenic and synthetic SeNP on tumor cells. Furthermore, biologic SeNP increased Bax gene expression compared with synthetic SeNP. Therefore, it can be concluded that the cytotoxic potency of biogenic SeNP is more than its synthetic form. The results also showed that treatment length was an undeniable factor in elevating the lethal effect of SeNP.

The biogenic and synthetic forms of SeNP exhibited a drastically killing effect after 72 h of treatment in comparison with 48 h of treatment. Kalhori et al. showed that miR579 increased Bax gene expression in glioblastoma cell line and induced apoptotic cell death [14]. Ozawa et al. used radiation therapy for mice harboring brain tumors. The results of the histopathological analysis demonstrated an increase in the level of apoptosis pathway through elevating Bax gene expression [15].
As mentioned, other studies have shown the effect of selenium nano-particle on cancer cell line and also they displayed the immuno-stimulatory role of SeNP on cancer cells via arresting cell cycle and promoting T cell cytotoxicity against tumor cell, therefore, it reinforced immunity, as well.

5. Conclusion

Our results demonstrated that biogenic and synthetic SeNP had cytotoxicity effects on A-172 nervous cell line, which is consistent with other studies. However, it seems that biogenic SeNP was more effective than its synthetic form. Therefore, it should be considered that the method of nano-particle construction may be an important parameter for its biological activity.

Ethical Considerations

Compliance with ethical guidelines

All ethical principles were considered in this article.

Funding

This research was supported by a grant from the Deputation of Research of Tehran University of Medical Sciences (Grant No.: 38504).

Author’s contributions

All authors reviewed and contributed to the manuscript prior to submission.

Conflict of interest

The authors declared no conflict of interests.

Acknowledgements

We thank Miss Fatemeh Asgar, Mr. Mohammad Mahdi Adib and Mr. Mohammad Mahdi Ghahari for their technical supports.

References


[14] Kalhori M, Irani S, Soleimani M, Arefian F, Kouhkhan F. Effect of miR-579 overexpression on the BAX and CDKN1A